Keryx keeps buy rating from Jefferies

Keryx Biopharmaceuticals Inc. was kept at a buy rating by Jefferies & Co., Inc. analyst Adam Walsh. In light of the company's pipeline expansion and start of two new KRX-0401 trials in hematologic tumors, Jefferies increased its price target to $25 from $20. Keryx announced the start of a multi-center phase 2 trial evaluating KRX-0401 in patients with refractory and relapsed leukemia. The company reported a fourth-quarter 2005 loss per share of $0.24, lower than the analyst's estimate of a loss of $0.20, and $0.05 lower than Street consensus. Shares of the New York City pharmaceutical company were down 14 cents, or 0.80%, at $17.46 on volume of 482,396 shares versus the three-month running average of 372,877 shares. (Nasdaq: KERX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.